| MRA Prescribed at Discharge (N = 365) | MRA Not Prescribed at Discharge (N = 1098) | Unadjusted Odds Ratio for MRA Prescription (ref = no MRA) (95% CI) | Adjusted Odds Ratio for MRA Prescription (ref = no MRA) (95% CI) | Interaction between MRA and Principal/ Secondary Diagnosis, p-value |
---|---|---|---|---|---|
30-day Readmission | 81 (22.2%) | 237 (21.6%) | 1.04 (0.78–1.38) | 1.14 (0.84–1.57) | 0.53 |
180-day Readmission | 159 (43.6%) | 509 (46.4%) | 0.89 (0.70–1.13) | 0.86 (0.67–1.11) | 0.14 |
30-day Mortality | 11 (3.0%) | 27 (2.5%) | 1.23 (0.61–2.51) | 1.42 (0.67–3.03) | 0.34 |
180-day Mortality | 34 (9.3%) | 112 (10.2%) | 0.90 (0.60–1.35) | 1.17 (0.76–1.79) | 0.35 |
30-day Heart Failure Readmission | 27 (7.4%) | 49 (4.5%) | 1.71 (1.05–2.78) | 1.60 (0.95–2.68) | 0.13 |
180-day Heart Failure Readmission | 76 (20.8%) | 170 (15.5%) | 1.44 (1.06–1.94) | 1.02 (0.72–1.44) | 0.45 |
30-day Hyperkalemia Readmission | 7 (1.9%) | 13 (1.2%) | 1.63 (0.65–4.12) | 1.92 (0.70–5.24) | 0.62 |
180-day Hyperkalemia Readmission | 19 (5.2%) | 52 (4.7%) | 1.10 (0.64–1.89) | 1.00 (0.55–1.84) | 0.81 |